Publications by authors named "F Suzan"

Claim this Profile
E
Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO.
Gurdeep Parmar, Marcelo Capra, Fernanda Seguro, Vania Hungria, Meletios-Athanasios Dimopoulos, Florence Suzan

Blood Cancer J· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.
Sikander Ailawadhi, Ivan Špička, Andrew Spencer, Jin Lu, Albert Oriol, Florence Suzan

J Clin Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.
Sikander Ailawadhi, Ivan Špička, Andrew Spencer, Jin Lu, Albert Oriol, Florence Suzan

J Clin Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plain language summary on subcutaneous administration of isatuximab in people with relapsed and/or refractory multiple myeloma.
Hang Quach, Gurdeep Parmar, Enrique M Ocio, Miles Prince, Albert Oriol, Florence Suzan

Future Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous administration of isatuximab in patients with multiple myeloma by an on-body delivery system: results of a nurse survey.
Nuria Sánchez Avello, Paula Calvo Pajares, Paul Cordero, Florence Suzan, Connie Barlas

Front Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis